Trident Texofab

What is the bonus history of the Trident Texofab?

Trident Texofab issued a bonus on August 11, 2020, in the ratio of 14:10, granting shareholders 14 additional shares for every 10 shares held, with a record date of August 12, 2020.

Trident Texofab has a bonus history that includes a notable issue on August 11, 2020. The company announced a bonus in the ratio of 14:10, meaning that for every 10 shares held, shareholders received an additional 14 shares. The record date for this bonus was August 12, 2020. If you have any more questions about Trident Texofab or need further details, feel free to ask!

Has Trident Texofab declared dividend?

Yes, Trident Texofab Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of July 18, 2019. However, the dividend yield is 0%, as there have been no dividend returns in recent periods, despite strong price returns.

Trident Texofab Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 18 Jul 19<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6 Months period, the price return was 57.14%, the dividend return was 0%, resulting in a total return of 57.14%.<BR><BR>In the 1 Year period, the price return was 356.13%, the dividend return was 0%, resulting in a total return of 356.13%.<BR><BR>In the 2 Years period, the price return was 234.83%, the dividend return was 0%, resulting in a total return of 234.83%.<BR><BR>In the 3 Years period, the price return was 101.25%, the dividend return was 0%, resulting in a total return of 101.25%.<BR><BR>In the 4 Years period, the price return was 460.32%, the dividend return was 0%, resulting in a total return of 460.32%.<BR><BR>In the 5 Years period, the price return was 545.26%, the dividend return was 0%, resulting in a total return of 545.26%.<BR><BR>Overall, Trident Texofab has declared a dividend, but it has not contributed to any yield in recent periods, as indicated by the 0% dividend yield. The company has shown strong price returns across all periods, suggesting robust performance despite the lack of ongoing dividends.

Who are the peers of the Trident Texofab?

Trident Texofab's peers include Bhilwara Tech, Axita Cotton, Manomay Tex Indi, and others. Trident Texofab leads in 1-year returns at 449.91%, while Axita Cotton has the lowest at -43.27%.

Peers: The peers of Trident Texofab are Bhilwara Tech, Axita Cotton, Manomay Tex Indi, Bhatia Communic., Super Sales Ind., Virat Industries, Zodiac Cloth. Co, Suditi Industrie, Shiva Texyarn, and Bannari Amm Spg.<BR><BR>Quality Snapshot: Excellent management risk is observed at Axita Cotton, while Average management risk is found at Manomay Tex Indi, Bhatia Communic., and Virat Industries, and the rest. Below Average management risk is present at Bhilwara Tech, Trident Texofab, Super Sales Ind., Zodiac Cloth. Co, Suditi Industrie, Shiva Texyarn, and the rest. Growth is rated as Good at Bhatia Communic., Average at Manomay Tex Indi and Virat Industries, and the rest, while Below Average growth is seen at Bhilwara Tech, Axita Cotton, Trident Texofab, Super Sales Ind., Zodiac Cloth. Co, Suditi Industrie, Shiva Texyarn, and the rest. Capital Structure is rated as Excellent at Axita Cotton, Average at Virat Industries, and Below Average at Bhilwara Tech, Manomay Tex Indi, Trident Texofab, Bhatia Communic., Super Sales Ind., Zodiac Cloth. Co, Suditi Industrie, Shiva Texyarn, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Trident Texofab at 449.91%, while the lowest is Axita Cotton at -43.27%. Trident Texofab's return significantly outperforms all peers. Additionally, Super Sales Ind., and Bannari Amm Spg. have negative six-month returns.

Who are in the management team of Trident Texofab?

As of March 2020, the management team of Trident Texofab includes Hardik J Desai (Chairman & Managing Director), Chetan C Jariwala (Whole-time Director), and several other directors and independent directors, totaling 13 members in diverse leadership roles.

As of March 2020, the management team of Trident Texofab includes the following individuals:<BR><BR>1. Hardik J Desai - Chairman & Managing Director<BR>2. Chetan C Jariwala - Whole-time Director<BR>3. Maniya H Desai - Director<BR>4. Natasha F Dsouza - Independent Director<BR>5. Ankita Jignesh Saraiya - Independent Director<BR>6. Mehul N Amareliya - Company Secretary<BR>7. Deepak P Gandhi - Director<BR>8. Vrusti B Patel - Additional Independent Director<BR>9. Manish Dhirajlaa Halwawala - Additional Director<BR>10. Sanju Patel - Company Secretary<BR>11. Ashwinbhai Desai - Additional Director<BR>12. Rushi Hemantkumar Jagani - Director<BR>13. Mishal Shailesh Patel - Additional Director<BR><BR>This team comprises a mix of directors, independent directors, and company secretaries, reflecting a diverse leadership structure.

What does Trident Texofab do?

Trident Texofab Ltd is a Micro Cap company in the Garments & Apparels industry, incorporated in 2008 and converted to a Public Limited Company in 2017, with recent quarterly net sales of 382 Cr and net profit of 5 Cr as of March 2025. Key metrics include a market cap of INR 300 Cr, P/E of 119.00, and a debt-equity ratio of 2.28.

Overview:<BR>Trident Texofab Ltd operates in the Garments & Apparels industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Trident Texofab Limited was originally incorporated as a Private Limited Company on September 05, 2008, and was later converted into a Public Limited Company on June 06, 2017. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 382 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 5 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 300 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 119.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 2.28 <BR>Return on Equity: 13.99% <BR>Price to Book: 16.22 <BR><BR>Contact Details:<BR>Address: 2004 2nd Flr North Extension, Nodh 4/1650 Sahara Darwaja Surat Gujarat : 395003 <BR>Tel: 91-261-2451284/2451274 <BR>Email: info@tridentexofab.com <BR>Website: http://www.tridenttexofab.com

Who are the top shareholders of the Trident Texofab?

The top shareholder of Trident Texofab is promoter Hardik Jigishkumar Desai with 14.15%, followed by public shareholder Savitriben Mahendrabhai Shah at 1.44%. Individual investors collectively hold 59.36%, with no institutional or pledged promoter holdings.

The top shareholders of Trident Texofab include Hardik Jigishkumar Desai, who is the promoter with the highest holding at 14.15%. The highest public shareholder is Savitriben Mahendrabhai Shah, holding 1.44%. Additionally, individual investors collectively hold a significant portion of 59.36%. There are no institutional holdings from mutual funds or foreign institutional investors, and there are no pledged promoter holdings.

How big is Trident Texofab?

As of 24th July, Trident Texofab Ltd has a market capitalization of 301.00 Cr, with Net Sales of 122.06 Cr and a Net Profit of 2.51 Cr reported in the latest four quarters.

As of 24th July, Trident Texofab Ltd has a market capitalization of 301.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Trident Texofab reported Net Sales of 122.06 Cr and a Net Profit of 2.51 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 16.26 Cr and Total Assets of 81.90 Cr.

How has been the historical performance of Trident Texofab?

Trident Texofab has shown steady growth in net sales, increasing from 49.93 Cr in Mar'21 to 122.06 Cr in Mar'25, with profits also rising significantly. However, cash flow from operating activities turned negative in Mar'25, indicating challenges in cash management despite overall financial growth.

Answer:<BR>The historical performance of Trident Texofab shows a steady increase in net sales and overall financial growth over the years.<BR><BR>Breakdown:<BR>Trident Texofab's net sales have shown a consistent upward trend, rising from 49.93 Cr in Mar'21 to 122.06 Cr in Mar'25. Total operating income followed a similar pattern, reaching 122.06 Cr in Mar'25, up from 90.96 Cr in Mar'20. The company's total expenditure, excluding depreciation, also increased, amounting to 116.58 Cr in Mar'25, compared to 47.05 Cr in Mar'21. Operating profit (PBDIT) has fluctuated, peaking at 8.78 Cr in Mar'25, while profit before tax reached 2.58 Cr in the same year. Profit after tax has also improved, standing at 2.51 Cr in Mar'25, up from 0.35 Cr in Mar'21. The company's total assets grew significantly from 55.68 Cr in Mar'20 to 100.58 Cr in Mar'25, while total liabilities increased from 20.37 Cr to 26.50 Cr during the same period. Cash flow from operating activities turned negative in Mar'25 at -13.00 Cr, contrasting with positive cash flows in previous years. Overall, Trident Texofab has demonstrated growth in sales and profits, despite some challenges in cash flow management.

Is Trident Texofab technically bullish or bearish?

As of December 3, 2025, the trend is mildly bullish, supported by daily moving averages and Bollinger Bands, though caution is advised due to a mildly bearish weekly MACD and bearish monthly RSI.

As of 3 December 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating mild bullishness and the Bollinger Bands showing a mildly bullish trend on both weekly and monthly time frames. However, the weekly MACD is mildly bearish and the monthly RSI is bearish, which suggests some caution. The KST remains bullish on both weekly and monthly charts, providing some support to the mildly bullish outlook. Overall, while there are mixed signals, the prevailing trend is mildly bullish.

Is Trident Texofab overvalued or undervalued?

As of December 4, 2025, Trident Texofab is considered very expensive with a PE ratio of 171.99 and significantly higher valuation metrics compared to its peers, indicating that its impressive stock performance may not be justified by its fundamentals.

As of 4 December 2025, the valuation grade for Trident Texofab has moved from expensive to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE ratio of 171.99, an EV to EBITDA of 65.76, and a PEG ratio of 18.66, all of which are considerably higher than industry norms. <BR><BR>In comparison to its peers, Elitecon International has a PE ratio of 197.4, while Lloyds Enterprises stands at 24.29, highlighting the stark contrast in valuation metrics within the sector. Despite Trident Texofab's impressive stock performance, with a year-to-date return of 102.05% compared to the Sensex's 9.12%, the current valuation suggests that investors may be paying a premium that is not justified by the company's fundamentals.

When is the next results date for Trident Texofab Ltd?

The next results date for Trident Texofab Ltd is 12 February 2026.

The next results date for Trident Texofab Ltd is scheduled for 12 February 2026.

Are Trident Texofab Ltd latest results good or bad?

Trident Texofab Ltd's latest Q3 FY26 results are unfavorable, with a 49.56% drop in net profit and a 15.96% decline in revenue, marking the lowest quarterly revenue in seven quarters. The significant contraction in both operating and PAT margins indicates serious operational challenges for the company.

Trident Texofab Ltd's latest results for Q3 FY26 indicate a challenging situation for the company. The net profit decreased significantly by 49.56% quarter-on-quarter to ₹0.57 crore, marking a concerning decline. Revenue also fell by 15.96% from the previous quarter to ₹25.74 crore, which is the lowest quarterly revenue the company has seen in the past seven quarters. This decline in revenue reflects deteriorating demand conditions and potential market share erosion in the competitive garments sector.<BR><BR>Additionally, both operating and PAT margins contracted sharply, with the operating margin dropping to 6.37% and the PAT margin to 2.21%. This compression in margins highlights the pressures the company is facing in terms of profitability.<BR><BR>Overall, the results suggest that Trident Texofab is experiencing significant operational challenges, characterized by declining revenues and profitability. Investors may view these results as unfavorable, raising concerns about the company's future performance and sustainability.

Should I buy, sell or hold Trident Texofab Ltd?

Which are the latest news on Trident Texofab?

Why is Trident Texofab Ltd falling/rising?

As of 15-Apr, Trident Texofab Ltd's stock price is at Rs 63.85, reflecting a 5.0% increase and a significant 21.50% gain over the past week, outperforming the Sensex. Despite a year-to-date decline of 72.73%, recent positive trading activity indicates a potential recovery phase.

As of 15-Apr, Trident Texofab Ltd's stock price is rising, currently at Rs 63.85, reflecting a change of 3.04 (5.0%) upward. The stock has shown significant performance over the past week, gaining 21.50%, and has outperformed the benchmark Sensex, which only increased by 0.71% during the same period. Additionally, the stock has been on a consecutive gain streak for the last seven days, accumulating a total return of 33.89% in this timeframe.<BR><BR>Today's trading session saw the stock open with a gain of 3.17% and reach an intraday high of Rs 63.85, indicating strong investor interest. The rising investor participation is evident, with a delivery volume of 66.8k on April 13, which is 39.49% higher than the 5-day average delivery volume. Furthermore, the stock's performance today has outpaced the sector by 2.26%.<BR><BR>Despite a year-to-date decline of 72.73% and a one-year drop of 62.88%, the recent upward momentum suggests a recovery phase, supported by positive trading activity and increased liquidity, as the stock is liquid enough for trades of Rs 0.01 crore. Overall, the combination of strong recent performance, increased investor participation, and favorable trading conditions contributes to the rising stock price of Trident Texofab Ltd.